Presentation is loading. Please wait.

Presentation is loading. Please wait.

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.

Similar presentations


Presentation on theme: "Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic."— Presentation transcript:

1 Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (AlloPBHCT) with TBI-Based Conditioning Regimens  Michael Burns, BA, Anurag Singh, MD, Yali Zhang, MPH, George L. Chen, MD, Hong Liu, MD, PhD, Maureen Ross, MD, PhD, Philip L. McCarthy, MD, Theresa Hahn, PhD  Biology of Blood and Marrow Transplantation  Volume 20, Issue 2, Pages S30-S31 (February 2014) DOI: /j.bbmt Copyright © Terms and Conditions

2 Biology of Blood and Marrow Transplantation 2014 20, S30-S31DOI: (10
Biology of Blood and Marrow Transplantation  , S30-S31DOI: ( /j.bbmt ) Copyright © Terms and Conditions


Download ppt "Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic."

Similar presentations


Ads by Google